Gunther Spohn

Summary

Affiliation: Cytos Biotechnology AG
Country: Switzerland

Publications

  1. doi Exploiting viral properties for the rational design of modern vaccines
    Gunther Spohn
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich Schlieren, Switzerland
    Expert Rev Vaccines 7:43-54. 2008
  2. doi Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 38:877-87. 2008
  3. pmc A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
    Gunther Spohn
    Cytos Biotechnology, Schlieren, Switzerland
    Virol J 7:146. 2010
  4. ncbi A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 178:7450-7. 2007
  5. doi A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 43:716-22. 2013
  6. ncbi Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles
    Gunther Spohn
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    J Immunol 175:6211-8. 2005
  7. ncbi Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL
    Gunther Spohn
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    Adv Exp Med Biol 602:135-42. 2007
  8. doi Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis
    Stefan Freigang
    Molecular Biomedicine, Institute of Integrative Biology, ETH Zurich, Schlieren, Switzerland
    Eur J Immunol 41:2040-51. 2011

Detail Information

Publications8

  1. doi Exploiting viral properties for the rational design of modern vaccines
    Gunther Spohn
    Cytos Biotechnology AG, Wagistrasse 25, CH 8952 Zurich Schlieren, Switzerland
    Expert Rev Vaccines 7:43-54. 2008
    ..As an elucidative example, this review will describe the key immunogenic determinants of viruses and discuss how they can be harnessed for the development of tailor-made vaccines against a wide array of human diseases...
  2. doi Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 38:877-87. 2008
    ....
  3. pmc A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
    Gunther Spohn
    Cytos Biotechnology, Schlieren, Switzerland
    Virol J 7:146. 2010
    ..Although these vaccines were shown to protect from disease in animal models, multiple injections and/or strong adjuvants were required to reach efficacy, underscoring the need for more immunogenic, yet safe DIII-based vaccines...
  4. ncbi A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis
    Gunther Spohn
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    J Immunol 178:7450-7. 2007
    ....
  5. doi A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis
    Alain C Tissot
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 43:716-22. 2013
    ..In summary, vaccination against IL-1α protected ApoE(-/-) mice against disease, suggesting that this may be a potential treatment option for atherosclerosis...
  6. ncbi Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles
    Gunther Spohn
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    J Immunol 175:6211-8. 2005
    ....
  7. ncbi Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL
    Gunther Spohn
    Cytos Biotechnology, Zurich Schlieren, Switzerland
    Adv Exp Med Biol 602:135-42. 2007
  8. doi Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis
    Stefan Freigang
    Molecular Biomedicine, Institute of Integrative Biology, ETH Zurich, Schlieren, Switzerland
    Eur J Immunol 41:2040-51. 2011
    ..These findings suggest a common pathway through which oxidative stress and metabolic danger signals converge and mutually perpetuate the chronic vascular inflammation that drives atherosclerosis...